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The ErbB receptor family is dysregulated in many cancers, and
its therapeutic manipulation by targeted antibodies and kinase
inhibitors has resulted in effective chemotherapies. However,
manymalignancies remain refractory tocurrent interventions.We
describe a new approach that directs ErbB receptor interactions,
resulting in biased signaling andphenotypes.Due to known recep-
tor-ligandaffinities and thenecessityofErbBreceptors todimerize
to signal, bivalent ligands, formed by the synthetic linkage of two
neuregulin-1 (NRG)moieties, twoepidermalgrowthfactor (EGF)
moieties,oranEGFandaNRGmoiety, canpotentiallydrivehomo-
typic receptor interactions and diminish formation of HER2-con-
taining heterodimers, which are implicated in manymalignancies
and are a prevalent outcome of stimulation by native, monovalent
EGF, or NRG. We demonstrate the therapeutic potential of this
approach by showing that bivalentNRG (NN) can bias signaling in
HER3-expressing cancer cells, resulting in somecases indecreased
migration, inhibited proliferation, and increased apoptosis,
whereasnativeNRGstimulation increased themalignantpotential
of the same cells. Hence, this new approach may have therapeutic
relevance inovarian,breast, lung,andothercancers inwhichHER3
has been implicated.
Members of the epidermal growth factor receptor (EGFR6/
HER/ErbB) family, EGFR, HER2, HER3, and HER4, regulate
diverse cell behaviors. The growth of many cancers is driven by
mutation or overexpression of these receptors or their ligands
(1, 2). Thus, numerous therapeutics directed at blocking signal-
ing by this receptor family are in clinical development or use (1,
3–8). Overwhelming evidence supports the concept that
ligand-induced activation of HER family members requires
dimerization or oligomerization (1, 2, 9–11). Family members
EGFR, HER3, and HER4 each have multiple known ligands,
which are often produced in autocrine fashion to regulate cel-
lular homeostasis or stress responses (12, 13). Although HER2
lacks known ligands, it heterodimerizeswith other familymem-
bers to form potent signaling complexes (10, 14). HER2 over-
expression is found in up to 30% of breast cancers (4, 14), where
contributions to themalignant phenotype are attributed at least
in part to heterodimerization with HER3 (7, 14), which has a
weak or inactive kinase but signals as a scaffold in partnership
with other receptors (15, 16). Furthermore, in cancers of lung,
breast, brain, and neck, where overexpression and/or mutation
of EGFR are involved, interactions with HER2 or HER3 are
often implicated in driving malignancy (14, 17). Thus, targeted
disruption of particular dimers of ErbB receptors has been
extensively explored for cancer therapy (6, 7); however, such
strategies generally work only in a subset of patients, and resis-
tance often emerges (4, 17–19). The mixed success of these
approaches in clinical outcomes underscores the complexity of
interactions and adaptations in the EGFR family signaling net-
work and the need for additional tools and approaches for per-
turbing the network.
Although multivalency is not a recognized feature of HER
family ligands, it drives receptor oligomerization in other
receptor systems, such as the CD95/FasL system (20).We spec-
ulated that bivalent HER family ligands might be a broadly use-
ful approach to manipulate HER family receptor associations.
We created a panel of bivalent ligands by linking together two
neuregulin-1 (NRG) moieties (ligand for HER3 and HER4),
two epidermal growth factor (EGF)moieties (ligand for EGFR),
or an EGF and a NRGmoiety via a protease-resistant spacer of
sufficient length to allow the two ligands to bind sites in adja-
cent (dimerized) receptors (Fig. 1A). These bivalent ligands
may thus serve to drive particular homotypic or heterotypic
receptor interactions (dimerization, oligomerization, or other
modes of association) at the expense of others, thus functionally
altering signaling and phenotypic outcomes compared with
their native, monovalent counterparts.
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We applied these new tools to test the hypothesis that a biva-
lent ligand incorporating twoHER3 ligandmoietiesmight drive
stable, unproductive homotypic association of HER3, thereby
sequestering ligand-bound HER3 from undesirable signaling
partnerships, especially with HER2 (Fig. 1B). HER3 has
emerged as a nexus for funnelingmalignant signals fromEGFR,
HER2, and c-MET into the PI3K/Akt pathway (16). Because
HER3 has weak kinase activity (15), homotypically associated
HER3may be incapable of activating downstream signaling path-
ways. We show here that a HER3 binding bivalent NRG ligand
(NN) induces differential behavior in numerous cancer cell lines
comparedwithnative,monovalentNRG. In some cases treatment
with NN resulted in suppression of malignant phenotypes; thus,
sequestration ofHER3 usingNNmay represent a novel therapeu-
tic modality for HER3-dependent cancers.
EXPERIMENTAL PROCEDURES
Protein Production and Characterization—Coding DNA for
fusion proteins (as shown in supplemental Table S1) consisting
of human sequences of EGF or NRG domains, protease resis-
tant hydrophilic spacers, and heterospecific coiled coil domains
were designed in silico (VectorNTI) and ordered as whole gene
products with an Escherichia coli codon bias from GeneArt
(Regensburg, Germany). Coding sequences were amplified by
PCRmutagenesis with flanking restriction sites to permit clon-
ing into pMAL-c2X (New England Biolabs) expression vectors.
All expression constructs were sequenced before transforma-
tion into the E. coli expression strain BL21(DE3)pLysS (Strat-
agene). Transformed strains were initially grown to an optical
density0.6 with agitation at 37 °C, then brought to 25 °C, and
protein expression was induced with a single pulse of 100 nM
IPTG for 4 h. Protein was harvested after cell lysis with Bug-
Buster MasterMix (Novagen) supplemented with PMSF and
protease inhibitor mixture (Sigma). Lysates were clarified by
centrifugation at 3500  g for 1 h at 4 °C. Clear lysate was
subjected to purification on amylose resin and Factor Xa cleav-
age in accordance with manufacturer’s protocol. Purified pro-
teins were analyzed by Coomassie staining of SDS-PAGE,
immunoblotting, and mass spectrometry. Coomassie staining
revealed a single purified band for all proteins, as confirmed by
mass spectrometry. Immunoblots confirmed the presence of
full-length protein when probed for terminal epitopes. Bind-
ing-deficient versions of EC and EN were derived from previ-
ously described EGF mutant XVI (21) and were created via
using a site-directed mutagenesis kit (Qiagen). Bioactivity of
purified fractions was confirmed by in vitro cell response versus
native ligands EGF and NRG-1 (Peprotech). Specificity for HER
receptor activation was assessed using the pan-HER kinase inhib-
itor N-(4-((3-chloro-4-fluorophenyl)amino)pyrido[3,4-d]pyrimi-
din-6-yl)2-butynamide (Calbiochem #324840).
Validation of Coiled Coil Interaction—Coiled coil interac-
tions between heterospecific pairs (i.e. EC EN, EC NN, and
NCNN) were characterized via an immunofluorescent bind-
ing assay as described in Moll et al. (22), with similar results.
Controls included non-biotinylated ligand to measure nonspe-
cific adsorption and staining of biotinylated ligandwith second-
ary antibody to control for variations in bound ligand, and data
were fitted to a one-parameter binding isotherm, revealing a
sub-pM affinity. Coiled coil binding was also confirmed by far
Western blotting by spotting 0.5 l of sample ligand binding
partner and controls in duplicate at 1 mM concentration onto a
nitrocellulose membrane that was pre-wetted with 1 transfer
buffer (4:1 MilliQ water:methanol and MES buffer). Mem-
branes were washed 3 times with 20 mM Tris-buffered saline
Tween 20, pH 7.4 (TBST), then blocked for 1 h with blocking
buffer (OBB, LicorOdyssey). Biotinylated cognate binding pro-
teins were then added to the blocking buffer at 100 nM and
incubated overnight at 4 °C. Themembranes were thenwashed
3 with TBST, probed for 1 h with IR dye-conjugated strepta-
vidin (Rockland) diluted 1:10,000 in OBB, washed 3 in TBST,
and scanned on a Licor Odyssey IR scanner. Coiled coil binding
was also confirmed by surface plasmon resonance on a Bia-
cor2000 instrument using a streptavidin-coated gold analysis
chip. Biotinylated EC (or NC) was immobilized on the chip sur-
face and brought to equilibrium with running buffer. The con-
jugation of EC (orNC) to the chip surface exhibited a stable base
line within 90 s of flowing EC (or NC) and remained stable over
long buffer wash times, indicating a stable surface binding of EC
(or NC). Attempts to conjugate additional EC (or NC) showed
no change in base line, indicating saturation of the chip surface.
Cognate binding partner EN (or NN) was flowed over the sur-
face, and binding signal was collected.
Cell Lines—Human telomerase reverse transcriptase-im-
mortalized human mesenchymal stem cells (hTMSC) were a
gift fromDr. JunyaToguchida (KyotoUniversity, Kyoto, Japan).
HeLa cells were obtained from ATCC. HeLa and hTMSC were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS), 1% L-glutamine, 1%
non-essential amino acids, 1% sodium pyruvate, and 1% peni-
cillin/streptomycin. MCF-7 cells were obtained from ATCC
and were maintained in phenol red-free medium of the same
composition. All cell culture media and additives were pur-
chased from Invitrogen. For single-cell migration studies,
hTMSCweremaintained in a DMEMmedium containing 0.5%
dialyzed fetal bovine serum (FBS), 1% L-glutamine, and 1% pen-
icillin/streptomycin at 37 °C, 95% humidity, and 5% CO2.
H3255 and H1975 cells were a generous gift of Dr. Pasi Janne
(Dana Farber Cancer Institute). H1975 cells were cultured in
RPMI 1640 media with 10% FBS, 5 mM L-glutamine, 100
units/ml penicillin G, 100 g/ml streptomycin. H3255 cells
were cultured in RPMI 1640 plus the 10% FBS, 0.02 mg/ml
insulin, 0.01 mg/ml transferrin, 25 nM sodium selenite, 50 nM
hydrocortisone, 1 ng/ml epidermal growth factor, 0.01mM eth-
anolamine, 0.01 mM phosphorylethanolamine, 100 pM triiodo-
thyronine, 0.5% (w/v) bovine serum albumin, 0.5 mM sodium
pyruvate, 5 mM L-glutamine, 100 units/ml penicillin G, 100
g/ml streptomycin. H1299 cells were purchased from ATCC
and maintained in RPMI 1640 media with 10% FBS, 5 mM
L-glutamine, 100 units/ml penicillin G, 100 g/ml strepto-
mycin. MDA-MB-435 transductants were a generous gift of
Dr. Jeffrey Segall (Albert Einstein College of Medicine) and
were cultured as described (23). MDA-MB-453 cells were a
generous gift of Dr. Michael Yaffe (Massachusetts Institute of
Technology) andwere cultured inDMEMmediawith 10% FBS,
penicillin/streptomycin, and L-glutamine.
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Cell Signaling andMigration—HER4 inhibition experiments
inMCF-7 cells were performed after seeding into 12 well plates
at 250,000 cells per well in serum containingmedium and incu-
bation for 48 h. Cells were then serum-starved for 5 h before
ligand treatment. Anti-HER4 antibody clone H4.72.8 (Milli-
pore #05-478) was then added to the cells at 10 g/ml 30 min
before subsequent treatments. IC50 measurements were made
by dosing cells with concentrations of bivalent NN ligand in the
range of 1M to 1 fM for 10min followed by a pulse of 3 nMNRG
for an additional 10 min. This dose of NRG and end point time
were validated by generating a NRG dose response curve for
MCF-7 cells in the concentration range 1M to 1 fM for 20min.
3 nM NRG was the lowest dose that produced near maximal
pERK1/2 signal at 20 min. After all stimulation experiments,
cells were placed on ice, and medium was aspirated, washed
with ice-cold PBS, and lysed with lysis buffer (Calbiochem
#FNN0011).
ForWestern blotting, membranes were probedwith primary
antibodies (9106 pERK1/2, 2236 pEGFR, 9271 pAkt, 2241
pHER2, 21D3 pHER3, 4267 EGFR, 2242 HER2, all from Cell
Signaling Technology; sc-415 HER3 from Santa Cruz Biotech-
nology, ab63354 HER4 from Abcam) and secondary IR-Dye
conjugate antibodies (IR-Dye700/800, Rockland) and scanned
using a Licor Odyssey IR scanner (Licor Systems, Inc.). Quan-
tification of phosphorylated (pY) EGFR,HER2, andERK1/2was
carried out using Widescreen (EMD Biosciences) and Bio-
plex bead kits according to the manufacturer’s instructions.
Readouts were made on a Bioplex 200 System (Bio-Rad,
Luminex Technology). Linearity of the pYpanEGFR and
pERK1/2 assays was checked using varying ratios of stimulated
lysates from hTMSC or HeLa cells, and results were used to
determine the optimal loading per well. Where indicated, anti-
HER4 antibody H4.72.8 was added to cells at 10 g/ml 30 min
before subsequent treatments.
For transwellmigration experiments, hTMSCwere seeded in
HTS Fluoroblock transwell well chambers (BD Biosciences) in
DMEM  10% FBS medium and mitomycin-C (Calbiochem).
Cells were fixed, stained, and quantified after 18 h. The upper
chambers were emptied of medium and filled with 4% formal-
dehyde solution, washed 2with PBS, then incubated in SYTO
16 nuclear stain (Invitrogen) for 15 min. These were again
washed with PBS and then placed in a clean 24-well plate and
read using a SpectraMax M2e multi-well fluorescent plate
reader (Molecular Devices Corp.). A standard curve correlating
fluorescence with cell number was obtained by plating known
numbers of cells in a 12-well plate in culture medium contain-
ing mitomycin-C. Standard cell numbers were confirmed by a
ViCell hemocytometer (Beckman-Coulter).
For assessment of single cell chemokinesis, H1975 cells were
labeled with 10 M of Celltracker Green CMFDA (Invitrogen)
and seeded at 4000 cells/cm2 on a 5 g/cm2 fibronectin-coated
glass bottom 24-well dish (Mattek, Inc) in serum-free medium
overnight. Anti-HER4 antibody clone H4.72.8 was added to the
cells at 10 g/ml 30 min before subsequent ligand treatments.
Time lapse images were taken every 10 min for 12 h using a BD
CARVII spinning disk confocal with an Axio Observer Zeiss
microscope equipped with environmental control (37 °C, 5%
CO2). The “spots” function in Imaris (Bitplane, Zurich, Switzer-
land) was used to calculate cell centroids, and migratory tracks
of individual cells were generated using the Brownian motion
tracking algorithm. All generated tracks were thenmanually veri-
fied foraccuracyandmodifiedwhentheautomated logarithmpre-
sented errors. Cells undergoing division, death, as identified as the
release of fluorescence, or blebbing were not tracked. Wind-rose
plots were generated from the tracks produced from 30 randomly
chosen cells from the motile population and overlaying the start-
ing coordinates at the origin of the plots to graphically represent
average cell dispersion duringmigration.
To assess chemotaxis in MDA-MB-435 cells overexpressing
HER2 (MDA-MB-435-HER2), chamberswere precoated for 2 h
at 37 °C with 20 g/ml fibronectin. Cells were serum-starved
for 2 h and seeded at 20,000 cells/well in MEM media with
0.35%bovine serumalbumin (BSA) on top of chemotaxis cham-
bers (Neuro Probe, ChemoTx Disposable Chemotaxis System,
#101-8, 8-m pore size). Ligands were placed in the media of the
upper and lower chamber, whereas a gradient of recombinant
human neuregulin-1 (Peprotech) was formed by dosing to 1 nM in
the lower chamber only. The chemokinesis control had 1 nM
recombinant human neuregulin-1 in the upper and lower cham-
bers. After 4 h, non-migrated cells were wiped from the top,
and the chamber was washed with PBS, allowed to dry, and
frozen at 80 °C. Cells that migrated across the membrane
were quantified via the CyQuant assay (Invitrogen).
Non-small Cell Lung Carcinoma (NSCLC) Cell Proliferation
and Apoptosis—H3255 cells were seeded at 6000 cells per well
in 96-well plates overnight in complete media. Subsequently,
media were changed to serum-free (unless noted) media con-
taining designated doses of ligands, and the cells were incu-
bated an additional 48 h. Cell proliferation was assessed using
theCyQUANT-NFproliferation kit (Invitrogen). All other pro-
liferation experiments were carried out identically, with the
exception of initial seeding at 3500 cells/well for all cells except
MDA-MB-453, which were seeded at 2500 cells/well. For apo-
ptosis studies, H1975 cells were seeded in chamber slides
(Nunc, Rochester, NY) at 50,000 cells/cm2. 24 h later media
were aspirated and replaced by newmedia with andwithoutNC
(100 nM) or bivalent NN (100 nM) and incubated for additional
24 h. Caspase-3 was detected using a NucViewTM Caspase-3
Assay kit for live cells according to themanufacturer’s protocol.
For competition studies, all ligands were dosed simultaneously.
Receptor Binding and Aggregation—Binding assays were
facilitated by radiolabeling NC with 125I using the Bolton-
Hunter reagent (PerkinElmer Life Sciences) using standard
methods. Binding to ErbB3 extracellular domains was per-
formed by incubating a range of 125I-NC or 125I-NN concentra-
tions (0.1, 0.25, 0.5, 1, and 3 nM) with Fc-ErbB3 chimeras (R&D
Systems, Minneapolis, MN) (0.1 nM) in binding buffer (25 mM
HEPES, pH 7.4, 150mMNaCl and 1mg/ml BSA) for 3 h at 4 °C.
The bound complexes were pulled down with magnetic pro-
tein-A beads (New England Biolabs, Beverly, MA). The beads
were washed three times with binding buffer, and 125I-NC or
125I-NN associated with the beads was measured using a Coba
Auto-Gamma 5005 (Packard Instruments, Meridian, CT). For
binding to MCF-7 cells, which express NRG receptors HER3
and HER4, cells were plated at a density of 8  104/well in
24-well plates and grown to confluence. Cells were thenwashed
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with ice-cold binding buffer (25 mM HEPES, pH 7.4, in serum-
free RPMI containing 1 mg/ml BSA) and incubated for 10 min
at 4 °C to inhibit endocytosis and binding site turnover. 125I-NC
or 125I-NN with and without an excess amount of unlabeled
NC/NN or unlabeled recombinant human NRG (Peprotech)
(500 nM) were added to the cells and incubated for 3 h at 4 °C.
Unbound ligands were washed 3 with binding buffer, and
bound ligands were extracted with 10 mM Tris, pH 7.4, 1 mM
EDTA, 0.5% SDS for 15 min at room temperature. 125I-Labeled
protein was quantified using a -counter (Coba Auto-Gamma
5005).
ErbB3 aggregation was measured via the change in hydrody-
namic radius using a DynaPro Titan Dynamic Light Scatterer.
Receptor (soluble chimera Fc-ErbB3 extracellular domain, as
above) and ligandswere allowed to interact overnight at 4 °C, 20
l of sample were loaded into a frosted cuvette, and 10 10-s
readings were recorded. Data were normalized to the radius of
receptor alone.
Cellular Imaging—For imaging studies, glass coverslips that
were previously etched using sulfuric acid, sterilized, and
coated with 3 g/ml of human fibronectin (Sigma) in phos-
phate-buffered saline (PBS) were used. 1% (w/v) BSA (Sigma) in
PBS was then added to each coverslip for 1 h to block any
uncoated regions, and coverslips were washed before seeding
with hTMSC at 4000 cells/cm2 overnight (16 h) in standard
culture conditions (37 °C, 5% CO2). Ligands were diluted to
appropriate concentrations (100 nM) in quiescent media, and
cells were stimulated with either EGF (EN), EGF-EGF bivalent
ligand (EE), ormedia alone for 2min.Mediawas then aspirated,
and cells were subsequently fixed with warm (37 °C) 4% form-
aldehyde solution in PHEM buffer (PIPES, HEPES, EGTA, and
MgSO4, pH 7.0) for 10 min at room temperature. A PBS wash
removed any excess 4% formaldehyde. Nonspecific binding of
antibodies was blocked by incubating the coverslips with block-
ing buffer (10% BSA in PBS) for 30 min before antibody expo-
sure. The goat polyclonal IgG anti-EGFR (sc-03-g, Santa Cruz
Biotechnology) and the Alexa Fluor 594 donkey anti-goat IgG
(Invitrogen) were each diluted to working concentrations in
blocking buffer. Coverslips were first exposed to the primary
antibody (goat anti-EGFR) for 1 h at room temperature fol-
lowed by 5 min washes with washing buffer (0.5% w/v BSA in
PBS). The anti-goat IgG antibody incubation followed for 1 h at
room temperature in the dark. Coverslips were stained with
DAPI pro-long gold (Invitrogen), mounted, and sealed. Images
were captured with a 60 objective (2  2 binning) on an
Olympus IX71 inverted microscope using Softworx software
for image acquisition.
Statistical Analysis—Data are presented as the mean  S.E.
unless otherwise indicated. Unless noted, statistical signifi-
cance was determined based on two-way analysis of variance.
Statistical significance for transwell migration was determined
by Student’s t test, and whereas statistical analysis of single cell
migration was evaluated using a Kruskal-Wallis nonparametric
test with a Dunn’s post-test.
RESULTS
Design and Validation of Bivalent Ligands—To explore
potential signal-biasing effects across the HER family, bivalent
engineered ligands were constructed in a modular fashion (Fig.
1A) by synthesizing fusion proteins of monomeric ligands
(NRG and/or EGF) with a protease-resistant spacer (24) and a
high (fM) affinity coiled coil domain (22) using cloning, expres-
sion, and purification strategies described under “Experimental
Procedures.” Reports analyzing ligand binding to EGFR and
HER3 suggested that receptor binding and activationwould not
be impaired bymodification of either the N or C terminus (25–
27). Bivalent ligands were designed using the crystal structure
of the EGF-bound homodimerized extracellular domain of
EGFR in which native ligands assume an anti-parallel orienta-
tion with respect to their termini and are separated by10 nm
(28) (Fig. 1A). The EGF and NRG component protein designs
were based on the same geometrical parameters given the close
similarity in ligand structure and receptor/ligand interactions
(25, 29). Thus, N-terminal modified constituents (EGF (EN) or
NRG (NN)) could be joined to C-terminal modified constitu-
ents (EGF (EC) or NRG (NC)) through high affinity heterospe-
cific coil interactions (see “Experimental Procedures”). Combi-
nation of these individual fusion proteins resulted in the
bivalent ligands NRG-NRG (NCNN, abbreviated as NN), EGF-
EGF (ECEN, abbreviated as EE), and EGF-NRG (EN), with EGF
or NRG moieties separated by a flexible spacer of total length
20 nm.
Monovalent NN and NC both activated ERK1/2 in a compa-
rable fashion to NRG in themammary tumor lineMCF-7 (sup-
plemental Fig. S1, A and C), which expresses both HER3 and
HER4 (30–33) (supplemental Fig. S2). It is notable that
although unstimulated MCF-7 cells express low (often unde-
tectable byWestern analysis) levels of HER4, as seen in supple-
mental Fig. S2, NRG-stimulation is reported to induce prolifer-
ation in these cells, resulting at least partially from signaling
downstream of HER4-phosphorylation (34). Additionally,
monovalent EN and EC activated ERK1/2 in a fashion compara-
ble with EGF in HeLa cells (supplemental Fig. S1, B and D),
which express both EGFR and HER2 (supplemental Fig. S2).
HER3 is a weak kinase that signals through interactions with
other receptors, including HER2, and such interactions are
associated with malignant phenotypes (7, 15, 35, 36). Unligan-
ded HER3 is reported to exist in an autoinhibited, associated
state on the cell surface (2, 25, 35, 37, 38). Native NRG does not
induce homodimerization of HER3 (9, 39, 40) but, rather,
appears to disrupt HER3 clusters. We predicted that NN
ligandswould opportunistically link adjacentHER3 into homo-
typic associations, sequestering HER3 from interactions with
HER2 and other potential partners and thereby reducing both
HER3 and HER2 activation (Fig. 1B). As an initial test system
for this hypothesis, we used the NSCLC line H3255, which
expresses HER3, HER2, and a mutant EGFR that cooperates
with HER3 to activate PI3K/Akt and is not known to express
HER4 (41) (supplemental Fig. S2).WhenH3255 cells were chal-
lenged with NRG (NC), they exhibited a dose-dependent phos-
phorylation of both HER3 and HER2 (Fig. 1C). In contrast, NN
failed to elicit similar activation ofHER3 andHER2, stimulating
slight phosphorylation only at low doses (Fig. 1C). This result is
consistent with the proposed model of HER3 sequestration
from HER2 by NN.
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We conducted several experiments to rule out the possibility
that the relative lack of HER2 and HER3 activation in H3255
arose from failure of NN to bind specifically to HER3. Using
125I-NC, we established that NN binds to the HER3 extracellu-
lar domain (ECD) in a specificmanner (supplemental Fig. S3A).
Furthermore, bivalent NN - but not monovalent NC, NN, NRG,
or bivalent EN - induced aggregation of the Fc-HER3 extracel-
lular domain as assessed by dynamic light scattering (supple-
mental Fig. S3B). Aggregation is expected only if both moieties
in the bivalent structure are competent to bind HER3, thus
presumably inducing oligomerization of the preformed HER3
extracellular domain homodimers, and the failure of EN to
FIGURE 1.Design and validation of bivalent ligands. A, bivalent ligands were formed via heterospecific coiled coil interactions of N- or C-terminal modified
EGF (EN, EC) or NRG (NN,NC) fusion proteins. Thus, formation of bivalent ligands with two EGF domains, two NRG domains, or one EGF and one NRG domain
is possible. B, possible mechanisms for the observed differences inmonovalent NRG compared with bivalent NN, in which NN fosters homodimerization
or homo-oligomerization of HER3 at the expense of heterodimers with HER2, are illustrated in the schematic. C, Western analysis is shown of pHER2 and
pHER3 in lysates fromNSCLC line H3255 cells stimulated for 15min bymonovalent NRG (NC) or bivalent NN (data are representative of two independent
experiments). D, the schematic illustrates a model for EE binding that facilitates EGFR homodimerization or homo-oligomerization, leading to at least
partial sequestration of EGFR from heterodimerization with HER2. E, HeLa cells were stimulated for 15 min with escalating doses of EGF or EE, lysed, and
analyzed by Luminex technology for pan-pY-EGFR or pan-pY-HER2 (n 3). AU, absorbance units. hTMSC were stimulated for 2 min with no ligand (F),
100 nMmonovalent EGF (G), or 100 nM bivalent EE (H); cells were fixed, and EGFR receptors were identified by immunofluorescent staining (red). F, G, and
H, nuclei were stained with DAPI (blue); scale bar 30 m, images are representative of 5 cells per condition (n 5) from a representative experiment
of 3 total.
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induce aggregation in this setting suggests that the effect
requires both neuregulin domains of NN to bind to a HER3
domain on twodifferent homodimers.We also determined that
bivalent 125I-NN exhibited specific binding to MCF-7 cells
(supplemental Fig. S3C).
In contrast to HER3, EGFR homodimers are competent to
signal. The presence of preformed EGFR homodimers or olig-
omers (42) may enable bivalent EE ligand to link proximal
EGFR into homotypic interactions upon binding (Fig. 1D). We,
therefore, predicted that stimulation of cells with EE would
result in activation of EGFR and downstream pathways along
with diminished activation ofHER2 comparedwith stimulation
with EGF.We first examined whether EE could activate signal-
ing downstream of EGFR in a specific manner. 10 nM EE effec-
tively stimulated ERK1/2 phosphorylation in HeLa cells, which
express comparable levels of EGFR andHER2 (43–46), at levels
similar to those observed by the constituent subunits EC and EN
(supplemental Fig. S4). Additionally, binding-deficient versions
of EC and EN were constructed by replacing a seven-amino acid
sequence in the EGF domain with a seven-amino acid sequence
from NRG (21). These proteins did not activate ERK1/2 at sig-
nificant levels above background but also did not prevent
ERK1/2 phosphorylation when paired with a complementary,
non-binding deficient fusion protein (supplemental Fig. S4).
Finally, combination of the binding-deficient EGF proteins to
form a binding deficient (BD) bivalent construct (EN-BD 
EC-BD) resulted in ERK1/2 phosphorylation at levels similar to
background at 10 nM, indicating that signaling effects mediated
by bivalent ligands are specific to the activity of their constitu-
ent members.
With evidence that EE activates signaling downstream of
EGFR in a specific manner, we examined the relative activation
of EGFR and HER2 in cells stimulated with monovalent com-
pared with bivalent ligand. At saturating doses, EGF and EE
activated EGFR in a comparable fashion in HeLa cells, but acti-
vation of HER2 was diminished by 50% in cells stimulated
with EE comparedwith EGF (Fig. 1E). This reduction of pHER2
is supportive of the hypothesis that EE partially sequesters
EGFR in homotypic interactions, as illustrated schematically in
Fig. 1D. We further hypothesized that, if EE does indeed drive
EGFR homotypic interactions, clustering of EGFR on a cell sur-
face may occur. To investigate the hypothesis, we assessed the
distribution of EGFR on intact cells via immunofluorescent
imaging. hTMSCcells stimulatedwith EE exhibited bright clus-
ters of labeled EGFR (Fig. 1H), whereas the EGFR surface dis-
tribution on EGF-stimulated cells was diffuse (Fig. 1G), more
closely resembling the receptor distribution of unstimulated
hTMSC (Fig. 1F).
In summary, we established that the engineered bivalent
ligands interact specifically with cell surfaceHER receptors and
that these interactions appear to have significant effects on acti-
vation of these receptors compared with those induced by
native HER receptor ligands.We predicted that treatment with
NN might suppress malignant phenotypes driven by HER3-
HER2 signaling; thus, we focused further investigations on this
engineered protein.
Bivalent NN Induces Differential Intracellular Signaling
Compared with Native NRG—HER3-HER2 receptor interac-
tions lead to intracellular signaling cascades that are associated
with many malignant behaviors (7, 15, 35, 36). We predicted
that such pathways would not be activated if bivalent NN
ligands sequester HER3 into homotypic interactions (Fig. 1B).
In hTMSC, which express EGFR, HER2, and HER3 (47), stim-
ulation with monovalent NRG (NC) induced a robust dose-de-
pendent phosphorylation until saturation at high doses of
ERK1/2, which is a well characterized member of the mitogen-
associated protein kinase family that regulates cellular pro-
grams such as proliferation, differentiation, and motility (Fig.
2A). In stark contrast, stimulation with bivalent NN resulted in
a nearly complete lack of pERK1/2 above the unstimulated con-
trol condition (Fig. 2A). Additionally, NC strongly induced
phosphorylation of Akt, a serine/threonine protein kinase that
regulates cell proliferation, apoptosis, transcription, andmigra-
tion in a dose-dependent manner in H3255 cells (Fig. 2B). In
contrast, bivalent NN did not induce Akt significantly above
control levels in these cells. Thus, in H3255 cells, NN-driven
cell surface receptor associations (Fig. 1C) appear to corre-
spond to altered intracellular protein phosphorylation (Fig. 2B),
indicating that NN can bias signaling in these cells.
BecauseNRGalso binds toHER4,NNmay interactwith both
HER3 and HER4 in cells that express both receptors. The
MCF-7 cell line expresses both HER3 and HER4, with HER4
being expressed at higher levels than most characterized cell
lines (30–34), and thus it is a useful model for analysis of HER4
contributions to signaling in cancer cells that co-express both
receptors (48), as ligand binding to HER4 can be blocked with
an antibody in parallel experiments. As expected, incubation of
MCF-7 cells with NC resulted in phosphorylation of both
ERK1/2 and Akt (Fig. 2C). Activation of these two downstream
signaling nodes was also observed whenMCF-7 cells were pre-
treated by incubation with an antibody that blocks ligand bind-
ing to HER4 before stimulation with NC (Fig. 2C), indicating a
prominent role for HER3 in these signaling pathways. Bivalent
NN also activated ERK1/2 and Akt in MCF-7 cells. This is
not surprising, as HER4 can form signaling-competent
homodimers (11), and such dimers may be induced by NN;
alternatively, the cell surface distribution of HER4 before stim-
ulation may involve proximity to other ErbB receptors, ena-
blingNN to act as a de factomonomeric ligand inducing oppor-
tunistic heterodimerization with HER2 or EGFR. As expected
by our findings in other cell lines lacking HER4 (Figs. 1B and 2,
A and B), where NN failed to activate downstream pathways,
phosphorylation of ERK1/2 and Akt after incubation with NN
was greatly diminished whenMCF-7 cells were pretreated with
an antibody that blocks ligand binding to HER4 (Fig. 2C), sug-
gesting that when HER4 is unavailable in these cells, NN binds
to and sequesters HER3.
To provide additional evidence that NN can block HER3-
mediated signaling, MCF-7 cells were incubated with or with-
out HER4 blocking antibody (10 min), then with NN at doses
0.1–100 nM (10 min), and then challenged with a saturating
dose of NRG. For cells treated with the HER4 blocking anti-
body, preincubation with NN before stimulation with NC abro-
gated downstream signaling in a dose (of NN)-dependentman-
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ner with an IC50 of 10 nM (Fig. 2D). This abrogation of
signaling is consistent with our observation that NN competes
with monovalent NRG in binding to MCF-7 cells (supplemen-
tal Fig. S3C) and suggests that it binds to and sequesters HER3
away from HER2 and other potential partners when HER4 is
unavailable. Interestingly, ERK1/2 activation was also moder-
ately attenuated in a dose-dependent fashion in the absence of
HER4 blocking antibody (Fig. 2D), a finding that is arguably
expected if the contributions of HER3 are silenced. Other fac-
tors, such as altered signaling by HER4 when liganded by NN,
may also contribute.
Bivalent NN Inhibits Migration and Proliferation and
Increases Apoptosis of Cancer Cells—NRG is known to stim-
ulate cell migration via multiple mechanisms, including via
HER2-HER3 heterodimers (23, 49–53). The inhibition of
this signaling axis with small molecule inhibitors of HER2
has been shown to reduce cell migration (54). Thus, we
hypothesized that sequestration of HER3 into homotypic
interactions via NN might reduce migration. Indeed, upon
the addition of NN, hTMSC chemotactic migration was sig-
nificantly reduced compared with the control condition as
well as to NC-stimulated cells (Fig. 3A). Furthermore, in
NSCLC line H1975, which expresses EGFR with the double
mutation L858R and T790M as well as HER2 and HER3 (55),
NN stimulation reduced chemokinesis relative to NRG-
stimulated and untreated control cells (Fig. 3, B and C). Also,
NRG-induced chemotaxis of MDA-MB-435 cells overex-
pressing HER2 (MDA-MB-435-HER2) was reduced in a
FIGURE 2. Bivalent NN induces differential intracellular signaling compared with native NRG. A, ERK1/2 phosphorylation was measured in hTMSC
stimulated by monovalent NRG (NC) and bivalent NN (n 8, data displayed as mean S.D.) after 15 min. B, Akt phosphorylation was assessed in H3255 cells
stimulated for 15 min by monovalent NRG (NC) and bivalent NN. Quantification via densitometry is shown below (data representative of 2 independent
experiments). C, MCF-7 cells incubated in the presence or absence of a HER4 blocking antibody were stimulated for 15min withmonovalent ligands NRG, NC,
or NN, or bivalent ligands NN or EN, and ERK1/2 and Akt phosphorylation was assessed via Western analysis (data representative of three independent
experiments; , untreated controls). D, at the indicated time points, MCF-7 cells were incubated in the presence or absence of HER4 blocking antibody
(anti-HER4) followed by NN stimulation and subsequent challenge with NRG. ERK1/2 phosphorylation was assessed by Western analysis (n 3). Reference
standards (normalized response 1) for A, B, andDwere set to the pERK1/2 level for 150 nMNRG (NC), the pAkt level for untreated cells, and the pERK1/2 level
for 1 nM NN (-anti-HER4, 3 nM NRG)-treated cells, respectively.
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dose-dependent manner upon exposure to NN (supplemen-
tal Fig. S5).
Based on the evidence that bivalent NN is capable of inhibit-
ing migration, we further hypothesized that NN may inhibit
additionalmalignant phenotypes associatedwithHER3-HER2-
driven signaling.WhenH3255 cells were dosed with NN over a
48-h period in serum-freemedia, we observed a decrease in cell
number compared with untreated controls, whereas NRG (NC)
stimulation led to proliferation compared with controls (Fig.
4A). This result indicates that biased signaling via NN (Figs. 1C
and 2B) results in suppression of malignant phenotypes.
We also examined potential proliferative effects in cells with
lower reported expression levels of HER3 to assess the specific-
ity and potency ofNN in this setting. NSCLC lineH1299, which
expresses EGFR and low levels of HER2 and HER3 (41) and no
HER4 (56) (supplemental Fig. S2), responded only weakly to
NRG (NC), even at high doses (supplemental Fig. S6). Predict-
ably, the effect of NN on these cells was also muted; yet, at the
highest dose administered, a significant reduction in prolifera-
tion compared with NC was observed as was a decrease in cell
number compared with untreated control (supplemental Fig.
S6). Thus, even in cells that are not highly sensitive to NRG
stimulation, we observed a differential effect of NN treatment,
supportive of the hypothesis that NN can bias signaling via
HER3 sequestration inmany ErbB receptor contexts. However,
clearly the most dramatic and potentially therapeutically rele-
vant differential effects of NN treatment are observed in cell
lines that respond most sensitively to NRG stimulation, as
would be expected.
In furtherance of this last observation,we examined signaling
and additional phenotypes in H1975 cells, which were previ-
ously shown to be highly sensitive to NRG stimulation (Fig. 3, B
and C), andMDA-MB-453 cells, a breast carcinoma line that is
also responsive toNRG (57). In these cells, NRG (NC) enhanced
proliferation of MDA-MB-453 cells in a dose-dependent man-
ner, whereasNN suppressed proliferation and induced a reduc-
tion in cell number compared with control (supplemental Fig.
S7A). These phenotypic effects could also be linked with differ-
ential phosphorylation of HER2 and HER3 by NRG (NC) and
NN (supplemental Fig. S7B). The appreciable levels of phos-
phorylation of HER2 and HER3 in these cells at high doses of
NN could be caused by HER3-HER4 heterotypic or HER4
homotypic interactions, as cell stimulation conducted in the
presence of a HER4-blocking antibody resulted in a near com-
plete reduction of NN-induced phosphorylation of HER3 and
HER2, whereas NC-mediated phosphorylation was relatively
unaffected (supplemental Fig. S7C).
H1975 cells responded more appreciably to NC stimulation,
with proliferation increased by 2–3-fold compared with con-
trols when cells were maintained in serum-free conditions for
48 h (Fig. 4B). In stark contrast, NN inhibited proliferation sig-
nificantly compared with NC under these conditions (Fig. 4B),
FIGURE 3. Bivalent NN inhibits cell migration. A, hTMSC on a transwell insert membrane were unstimulated () or stimulated by monovalent NRG (NC) or
bivalentNN, andcellsmigratingacross themembraneafter 18hwerequantifiedvia SYTO16nuclear staining (n3).B, representativewind roseplots ofH1975
cells stimulated for 12hby controlmedia, NC, orNNare shown.C, quantitationof cell speed fromH1975 single cellmigration studies (n30) is shown. The solid
line indicates untreated control cell mean speed, and the dashed lines indicate S.E, for control condition.
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and NN treatment also resulted in a decrease in cell number
compared with untreated controls. The disparate effects of
native NRG and bivalent NN ligands on proliferation of H1975
cells were also observed in culture medium containing serum
(supplemental Fig. S8). In the presence of serum, a source of
ligands for EGFR, c-MET, and other receptor-tyrosine kinases
expressed by H1975 cells, the effects of monovalent NRG (NC)
on proliferation were blunted compared with serum-free con-
ditions. However, bivalent NN still suppressed proliferation of
H1975 cells (supplemental Fig. S8), suggesting that HER3 is a
central nexus for funneling proliferation signals in these cells in
the presence of the multiple stimulants present in serum. The
reduced cell numbers observed in the presence of NN com-
pared with control cells were attributed in part to increased
apoptosis in the presence of NN, as H1975 cells cultured in the
presence of bivalent NN ligand exhibited a greater proportion
of cells that stained positive for activated caspase-3 (Fig. 4C).
To determine whether the divergent phenotypic effects
observed in H1975 cells could be attributed to both NN and
NRG acting through the same binding site (HER3), we assessed
cell proliferation in the presence of either monovalent NC or
bivalent NN and competing doses of the other ligand. 35 nM
NC-stimulated H1975 exhibited increased proliferation com-
pared with unstimulated cells in media containing serum, as
also shown in supplemental Fig. S8 (Fig. 4D). However, simul-
taneous co-stimulation with increasing doses of NN led to a
decrease in proliferation (Fig. 4D). In contrast, 35 nMNN-stim-
ulated cells, whereas exhibiting reduced proliferation com-
pared with untreated control as previously shown (supplemen-
tal Fig. S8), did not proliferate in response to increasing
(simultaneous) doses of NC. This may have occurred due to a
lack of receptor reorganization on the cell surface upon binding
of NC; if, as we hypothesize, HER3 receptors are sequestered
together by NN, replacement of a NRG domain of NN by a
native NRG via competition would seem unlikely to promote a
change in the receptor association with its nearest neighbors.
Finally, the phenotypic effects observed in H1975 cells were
also linked with differential HER2 andHER3 receptor phosphor-
ylation profiles attributed toNC andNN (supplemental Fig. S9).
Although NC induced dose-dependent increases in both
pHER3 and pHER2,NN stimulation led to only slight induction
of HER3 phosphorylation at high doses, whereas HER2 activa-
tion appeared to decrease in a dose-dependent manner. Intra-
cellularly, both ERK1/2 and Akt were phosphorylated resultant
from low doses of both NC andNN in these cells (supplemental
Fig. S9). However, whereas increased NC dosage led to in-
creased levels of pERK1/2 and pAkt, high doses of NN resulted
in diminished phosphorylation of both intracellular proteins,
mirroring the pattern observed for HER2 phosphorylation
(supplemental Fig. S9). Thus, these data are supportive of the
conclusion that bivalentNN interactswith surfaceHER3 recep-
tors and sequesters them from participation in HER2-associ-
ated signaling complexes, leading to reduced HER2 phos-
phorylation. The reduction in HER2-mediated signaling then
led to reduced activation of intracellular proteins (ERK1/2,Akt)
that play important roles in cell proliferation, survival, and
motility, and thus the cells exhibited reduced capacities in these
activities, as shown in Figs. 3, B and C (migration), 4D (apopto-
sis), and 4, B and C, and supplemental Fig. S8 (proliferation). A
similar phenomenon was also observed in H3255 cells, where
FIGURE 4. Bivalent NN inhibits proliferation and increases apoptosis of cancer cells.H3255 (A) and H1975 (B) cells were stimulatedwithmonovalent NRG
(NC) or bivalent NN in serum-free conditions for 48 h. Cellular activity relative to untreated control (100%) was quantified using the CyQUANT assay (n 4).
C, H1975 cellswere exposed toNNor controlmedia in thepresenceof serum for 24h and stained for activated caspase-3 (data representative of 2 independent
experiments). D, H1975 cells, in 10% serum media, were simultaneously stimulated with either 35 nM monovalent NRG (NC) or 35 nM bivalent NN and the
indicated doses (on the x axis) of the other ligand for 48 h (n 5, brightfield images to left of stained sections).
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differential receptor phosphorylation (Fig. 1C) was linked to
differential induction of intracellular signaling pathways (Fig.
2B) that led to differential phenotypic effects (Fig. 4A).
Thus, in multiple cell lines, we established that engineered
bivalent NN induces differential HER receptor phosphoryla-
tion comparedwith nativeNRG. These directed receptor inter-
actions, which are predictable based on knowledge of HER
ligand-receptor affinity interactions, biased downstream sig-
naling pathways, leading to unique and beneficial phenotypes.
DISCUSSION
The approach described here is a departure from traditional
methods used to influence HER receptor signaling. Small
molecule inhibitors target kinases, whereas antibody-based
approaches target receptor ectodomains and ligands (5, 14, 29).
Small molecule approaches also have risks of off-target toxicity,
whereas antibody-based approaches are limited by affinity
maxima, high dosing requirements, and relatively large molec-
ular weights (150 kDa) (58). Therapeutic options are further
limited forHER3 as it lacks significant kinase activity; hence, we
focused our attention on this important target and exploited
this deficiency. Although it is arguably counterintuitive to
silence a pathway by engaging the receptor with ligand, it is
possible that, compared with function-blocking antibodies,
bivalent ligands (particularly NN) may exhibit some therapeu-
tic advantage; e.g. by engaging the receptors in more favorable
steric associations for inhibiting interactions with other
partners, altering internalization rates, or through improved
tumor-penetrating properties.
Previous attempts to force hetero- and homodimerization of
EGFR and HER2 showed altered proliferation and migration
depending on the type of receptor dimer formed (59). However,
that approach relied on expression of modified receptors with
rapamycin binding domains to force particular receptor pair-
ings. The approachwe describe alters receptor interactions and
biases signaling with an exogenous method that does not
require genetic intervention. Another report describes exoge-
nous application of a surface-bound dimeric EGF ligand for
selective expansion of neural stem cells (60). In this study we
demonstrate enhanced versatility of bivalent ligands by incor-
porating NRG moieties and provide a conceptually new appli-
cation, inhibition of signaling. Furthermore, we establish the
potential to selectively bias signaling in a particular cell type,
based on its HER-family receptor expression profile, and to
potentially apply bivalent ligands in a therapeutic context.
There are several possible mechanistic interpretations for
how NN, which binds to HER3 (and HER4), inhibits receptor
activation, downstream signaling, and phenotypic behaviors. A
bias toward HER3 homotypic interactions by NN is arguably
anticipated. Several lines of evidence support the idea that
HER3 exists in a closely clustered state before ligand binding,
possibly in association with HER4 (9, 35, 37, 38, 61, 62), and all
cell lines used in this study exhibited low levels of HER4 com-
pared with HER3 (supplemental Fig. S2). Hence, bivalent NN
might be able to trap HER3 receptors, either linking them as
dimers or possibly resulting in a concatenation of cross-linked
dimers as shown in Fig. 1B. This interpretation is supported by
two consistent observations in our studies, which is that biasing
and/or inhibitory effects of NN increased with dose and that
low doses of NN produced similar results to corresponding
doses of native, monovalent NRG. At low NN doses, where
HER3 receptors may not be saturated and/or complete concat-
enation may not occur, HER3 may still be available for interac-
tion withHER2, as would be the case with stimulation by native
NRG. Upon increasing the dose of NN, if the proposed hypoth-
esis is true, complete concatenation or saturation of HER3 by
NN would prevent interaction with HER2, and thus result in
the differential signaling and phenotypic outcomes from NRG
that were observed in this study. In this case, the efficacy of NN
in biasing signaling would be dependent on the relative num-
bers and locations of HER receptors, disparities in which may
explain the different effects observed in different cell lines with
similar gross HER receptor profiles in this study. It is also nota-
ble that ligand-induced dimerization/homotypic association of
HER3 has rarely been reported, especially in a cellular context
(39, 62). Ligand binding is believed to unlock HER3 from the
clustered, inhibited state, allowing it to find and associate with
HER2 (or other partners). When HER3 partners with HER2,
activation of signaling likely requires tetramers or higher order
oligomers to overcome the kinase deficiency ofHER3, although
detailed structures and mechanisms of this activation process
are still not clear (37, 39, 40). It is, therefore, possible that biva-
lent NN could link two HER3 receptors facing each other, leav-
ing the dimerization face available for interactionwithHER2 or
other partners (i.e. instead of the concatenation with HER3, as
shown in Fig. 1B). If such “solo, facing-each-other” dimers are
indeed formed, they are likely constrained from proper (acti-
vating) interactions with HER2, as evidenced by the lack of
HER3-mediated signaling observed in the presence of NN.
In contrast to the near-complete inhibition of receptor acti-
vation and signaling observed with NN, our more limited study
of bivalent EE revealed that it activated cognate receptor EGFR
and only partially biased activation away from HER2 (Fig. 1E).
These results are consistent with amechanistic model in which
EEmay opportunistically bind to a variety of pre-formed EGFR
states (homodimers, oligomers, and heterodimers) that have
been reported by others to exist in dynamic equilibrium on the
cell surface (9, 42). Thus, EE may serve to stabilize dimers or
concatamers (Fig. 1D) upon binding to homotypically pre-as-
sociated EGFR via both EGF moieties and also may act as a
monomeric ligand upon binding to EGFR that is not homotypi-
cally pre-associated. It is also possible that EE induces a solo,
facing-each-other dimer that leaves the dimerization face avail-
able for interaction with HER2.
Potential mechanistic interpretations notwithstanding,
these studies suggest that a bivalent NN ligand could have ther-
apeutic applications. Recent findings point to HER3 interac-
tions with c-MET as a mechanism for therapeutic resistance
after treatment with various chemotherapeutic agents (19, 55,
63). Furthermore, HER3- and/or HER4-mediated autocrine
signaling may play an important role in certain types of ovarian
cancer (64). In that regard inhibition of proliferation of H1975
cells by NN is particularly interesting, as H1975 express HER4
at detectable levels (55) and would thus presumably bind NN
through both HER3 and HER4. HER4 responses can promote
proliferation of breast (48) and lung (56) cancers; thus, the abil-
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ity of NN to inhibit malignant phenotypes in cancer cells that
co-expressHER3 andHER4 is an encouraging observation. The
therapeutic implications of the EGF-containing bivalent
ligands are less clear. HER2 is implicated as an important part-
ner in the pathogenesis of certain EGFR-overexpressing tumors
(65), as HER2-EGFR dimers more strongly activate malignant
signaling pathways compared with EGFR homodimers (66). As
opposed to NN, EE and EN may bias signaling to alternative
productive pathways, making them less promising to pursue as
possible chemotherapeutics but of interest for future studies on
phenotypes relevant for regenerative medicine. More broadly,
bivalent ligandsmay be deployed as a new tool for dissecting the
complex systems biology of the EGFR family in developmental
biology, tissue regeneration, wound healing, and other physio-
logical and pathophysiological processes (67).
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